Swedish Orphan Biovitrum AB (publ) (Sobi) and Bioverativ Inc. announced that results from the Kids B-LONG Phase III clinical trial,...
Biogen Idec and Swedish Orphan Biovitrum AB (Sobi) released positive top-line results of the Kids A-LONG Phase III clinical study...
Swedish Orphan Biovitrum AB (publ) announced that the first patient has been dosed in the phase III, open-label, interventional XTEND-Kids study of efanesoctocog alfa (BIVV001) in paediatric subjects with severe haemophilia A .
Biogen Idec and Swedish Orphan Biovitrum AB announced positive top-line results of the Kids B-LONG Phase III clinical study that...
Sobi and Sanofi announced that the XTEND-Kids phase III pivotal study evaluating the safety, efficacy and pharmacokinetics of efanesoctocog alfa as once-weekly prophylaxis in previously treated patients under 12 years of age with severe haemophilia A met its primary endpoint
Applied Therapeutics, Inc. announced results from the ACTION-Galactosemia Kids study of govorestat (AT-007), a novel, oral, small molecule, central nervous system (CNS) penetrant Aldose Reductase inhibitor (ARI)
Everything in the world of diabetes is moving fast these days. Over the last few months, we have received extensive...
The Primary objective is to demonstrate the efficacy of dupilumab treatment compared with placebo in pediatric patients with active eosinophilic esophagitis (EoE) based on histologic improvement meeting validated histologic criteria.
Pivotal data from the Phase III XTEND-Kids study evaluating efanesoctocog alfa [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein] once-weekly prophylaxis in previously treated patients younger than 12 years of age with severe haemophilia A were presented in a late-breaking session at the Annual Meeting of the International Society on Thrombosis and Haemostasis (ISTH) in Montreal, Canada
New Phase III data from Bayer HealthCare's LEOPOLD Kids clinical trial investigating the safety and efficacy of BAY 81-8973, otherwise...